Trial Profile
A randomised, placebo-controlled study of two doses of oral 6R-BH4 [sapropterin] on vascular function in subjects with coronary artery disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sapropterin (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms OXBIO
- 26 Jul 2020 Status changed from recruiting to completed.
- 01 Sep 2010 Results presented at the ESC Congress 2010: Annual Congress of the European Society of Cardiology.
- 06 Aug 2008 The expected completion date (Feb 2009) added as reported by ClinicalTrials.gov.